Drug Profile
PT 2567
Alternative Names: PT2567Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Peloton Therapeutics
- Class Antihypertensives; Small molecules
- Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pulmonary arterial hypertension
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in USA
- 30 Jul 2019 Peloton Therapeutics has been acquired by Merck & Co
- 06 Mar 2018 Preclinical trials in Pulmonary arterial hypertension in USA (unspecified route) (Peloton Therapeutics pipeline, March 2018)